Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Tango Therapeutics, Inc. reported that Crystal Adam, its President, R&D, sold 54,345 shares of common stock on February 25, 2026. The open-market sale was executed at a weighted average price of $12.7741 per share under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025. Following this transaction, Adam directly owns 132,873 Tango Therapeutics common shares.
Adam Crystal filed a Form 144 reporting sales of company common stock. The filing lists 54,345 Restricted Stock Units identified for sale and reports 18,452 shares sold on 02/03/2026 for $226,300.30.
The filing names Morgan Stanley Smith Barney LLC as the broker and shows transaction and security details tied to restricted stock units dated 02/05/2024.
Tango Therapeutics, Inc. (TNGX) received an amended Schedule 13G/A showing that EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman now report zero beneficial ownership of the company’s common stock. As of December 31, 2025, each reporting person lists 0 shares beneficially owned and a 0% stake, with no sole or shared voting or dispositive power. The filing confirms they own 5 percent or less of the class. The parties also state they are filing jointly but expressly disclaim being part of a group and disclaim beneficial ownership beyond any pecuniary interest.
Tango Therapeutics, Inc. received an amended Schedule 13G from TCG Crossover Fund II, TCG Crossover GP II, and Chen Yu reporting beneficial ownership of 13,521,839 shares of common stock, representing 9.99% of the class.
The position consists of 12,762,094 common shares and 759,745 shares underlying pre-funded warrants that are exercisable within 60 days of the statement. Additional pre-funded warrants for up to 1,066,666 shares are excluded because a 9.99% Beneficial Ownership Limitation prevents exercise above that threshold. Ownership is calculated using 134,593,998 shares outstanding as of October 28, 2025, plus the exercisable warrant shares. The filers state the securities are not held for the purpose of changing or influencing control of Tango.
Woodline Partners LP filed an amended beneficial ownership report showing a significant passive stake in Tango Therapeutics, Inc.. Woodline reports beneficial ownership of 10,072,225 shares of Tango common stock, representing 7.5% of the class.
The percentage is calculated using 134,677,094 shares of common stock outstanding as of November 1, 2025, as disclosed in a company registration statement. Woodline, a Delaware investment adviser, reports sole voting and dispositive power over these shares, which are directly held by Woodline Master Fund LP.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tango Therapeutics. Woodline Master Fund has the right to receive dividends and sale proceeds from more than 5% of the common stock.
Tango Therapeutics, Inc. received an updated ownership report from Invus-affiliated investors and Raymond Debbane. As of December 31, 2025, Invus Public Equities directly held 7,068,444 common shares and Avicenna Life Sci Master Fund held 1,096,930 shares of Tango Therapeutics.
Through a chain of general partners and managing members, including Invus Public Equities Advisors, Invus Global Management, Siren, Avicenna GP and Ulys, Raymond Debbane may be deemed to beneficially own 8,165,374 shares, representing 6.1% of Tango’s common stock, based on 134,593,998 shares outstanding as of October 28, 2025. The reporting group certifies the shares were not acquired to change or influence control of the company.
Adage Capital Management, L.P. and affiliates report a 7.88% beneficial stake in Tango Therapeutics, Inc. They collectively hold 10,607,924 shares of Tango common stock, with shared voting and investment power and no sole authority reported.
The ownership percentage is based on 134,677,094 Tango shares outstanding as of November 1, 2025, as disclosed in a company registration statement. The investors state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tango Therapeutics.
Tango Therapeutics, Inc. filed an Amendment No. 4 to Schedule 13D/A reporting updated ownership by Third Rock Ventures entities. As of February 6, 2026, Third Rock Ventures IV, L.P. and its affiliated general partners reported shared voting and dispositive power over 6,374,574 shares of Tango common stock, representing approximately 4.74% of outstanding shares, based on 134,593,998 shares outstanding as of October 28, 2025. The amendment states that transactions described in Item 5(c) caused a decrease of over one percentage point in the aggregate ownership previously reported. These changes follow several open-market sales of Tango shares in January and February 2026.
Tango Therapeutics, Inc. received an amended Schedule 13G showing updated ownership by funds managed by Farallon Capital. As of the reporting date, the Farallon Funds hold 13,391,411 common shares and 2,159,792 pre-funded warrants, each warrant exercisable into one share.
The warrants are subject to a 9.99% Beneficial Ownership Limitation, so only 69,804 warrants are currently counted as exercisable within 60 days when calculating beneficial ownership. The amendment also records governance changes at Farallon: Avner A. Husen became a member/manager of the related general partners effective January 1, 2026, while Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles as of December 31, 2025, and may no longer be deemed beneficial owners. The filing is made on a passive basis under Rule 13d-1(c), with the group certifying the holdings are not for the purpose of changing or influencing control of Tango Therapeutics.
Tango Therapeutics Chief Financial Officer Daniella Beckman reported new equity awards and related tax sales. On February 2, 2026, she acquired 44,330 shares of common stock for $0, representing restricted stock units that vest in three tranches through February 2029, and received a stock option for 265,980 shares at an exercise price of $11.94 per share, vesting over four years.
On February 3, 2026, she sold 10,204 and 113 shares of common stock at weighted average prices of $12.2573 and $12.8971, respectively, under the company’s automatic “sell-to-cover” policy for tax withholding tied to RSU vesting. After these transactions, she held 184,297 shares of common stock and 265,980 stock options, all reported as directly owned.